Skip to content

Kalydeco Status In Germany

February 8, 2013

Per a article, Germany’s Federal Joint Committee (G-BA) says in a final assessment that Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) for Cystic Fibrosis (CF) provides a “significant degree of additional benefit for patients older than 12 and a marginal degree of benefit for patients ages 6-11 years.”

Vertex Pharmaceuticals and Germany’s Statutory Health Insurance Funds Association (GKV-Spitzenverband) will now negotiate a price for Kalydeco. In November 2012, Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) issues an assessment of Kalydeco’s cost to GKV-Spitzenverband of about EUR 52.3 million ($71.1 million) per year.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: